Published in Cancer on October 01, 2010
Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol (2011) 1.25
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol (2015) 0.95
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica (2013) 0.94
Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol (2013) 0.81
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol (2012) 0.80
Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009. Cancer Res Treat (2015) 0.79
Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution. Neurol Med Chir (Tokyo) (2013) 0.75
Safety and efficacy of primary central nervous system lymphoma treatment in elderly population. Neurol Sci (2015) 0.75
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Glioblastoma and other malignant gliomas: a clinical review. JAMA (2013) 4.99
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Clinicopathological features of and risk factors for multiple primary melanomas. JAMA (2005) 2.62
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Brain metastases. Neurol Clin (2003) 2.44
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 2.41
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med (2003) 2.33
Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol (2006) 2.32
The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg (2010) 2.26
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci (2003) 1.99
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (2006) 1.98
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology (2005) 1.91
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst (2010) 1.91
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
Cancer screening among patients with advanced cancer. JAMA (2010) 1.82
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer (2004) 1.81
Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma (2003) 1.77
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood (2010) 1.77
Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol (2005) 1.76
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol (2008) 1.75
Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology (2011) 1.74
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol (2006) 1.74
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 1.74
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol (2003) 1.73
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol (2008) 1.73
Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol (2004) 1.72
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol (2002) 1.62
Intracranial dural metastases. Cancer (2009) 1.59
Advancing the treatment of malignant glioma: act local, think global. Cancer Invest (2004) 1.59
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys (2008) 1.58
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc (2006) 1.57
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol (2002) 1.54
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol (2013) 1.54
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Chemotherapy for brain tumors--a new beginning. N Engl J Med (2005) 1.49
Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol (2004) 1.48
Multifocal stroke from tumor emboli. Arch Neurol (2009) 1.48
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma (2011) 1.45
Variates of survival in metastatic uveal melanoma. J Clin Oncol (2005) 1.45
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol (2005) 1.44
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology (2007) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol (2003) 1.41
Maintenance therapy for central nervous system lymphoma with rituximab. Leuk Lymphoma (2009) 1.39
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol (2003) 1.39
Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med (2004) 1.38